(Q38294622)

1 September 2017

1 reference

title

Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer (English)

1 reference

1 September 2017

0 references

1

1 reference

1 September 2017

Wojciech Kukwa

2

0 references

Cezary Szczylik

series ordinal

5

object named as

Cezary Szczylik

1 reference

1 September 2017

3

Anna Kornakiewicz

1 reference

1 September 2017

Fei Lian

4

1 reference

PubMed ID

25525857

1 September 2017

language of work or name

English

0 references

publication date

1 December 2014

1 reference

1 September 2017

1 reference

1 September 2017

10

1 reference

1 September 2017

2493-2508

1 reference

1 September 2017

15

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

1 September 2017

1 reference

The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Renal tumors with clear cells. A review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

An overview of renal cell cancer: pathology and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Loss of caspase 7 expression is associated with poor prognosis in renal cell carcinoma clear cell subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Caveolin 1 protein expression in renal cell carcinoma predicts survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

CD151 expression can predict cancer progression in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Differential role of CD133 and CXCR4 in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Expression of endothelin 2 and localized clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Expression and prognostic significance of Src family members in renal clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

High Jagged1 expression predicts poor outcome in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Loss of nuclear p27(kip1) and α-dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Prognostic implication of TIM-3 in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Increased expression of forkhead box M1 protein is associated with poor prognosis in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Erythrocyte sedimentation rate and anaemia are independent predictors of survival in patients with clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Treatment selection in metastatic renal cell carcinoma: expert consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Prognostic factors in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Expression of hypoxia inducible factor-1α and 2α in conventional renal cell carcinoma with or without sarcomatoid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primar

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Predictive markers in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Molecular biomarkers in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.162

21 January 2018

Identifiers

DOI

10.2217/FON.14.162

1 reference

1 September 2017

1 reference

PubMed ID

25525857